REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi
Go back to REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 9.07 +1.27 (16.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.80 | 52 Week High | $25.00 | |||
| Open | $8.52 | 52 Week Low | $7.07 | |||
| Day High | $9.65 | P/E | N/A | |||
| Day Low | $7.81 | EPS | $0.00 | |||
| Volume | 8,981,219 | |||||
